Bindi’s Masters thesis studied the use of plant viral nanoparticles for cancer immunotherapy in Steinmetz’ lab at Case.

Following her master’s, she worked at two industry startups where she researched non-invasive glucose monitoring and cancer cell intrinsic immunotherapy. Bindi focused on extending the Tuba-seq technology to model sequential tumorigenic events and intra-tumor heterogeneity via serial transductions, and is now working successfully with her old employer - Arcus Biosciences.